These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 39097431)

  • 41. Vascular toxic effects of cancer therapies.
    Herrmann J
    Nat Rev Cardiol; 2020 Aug; 17(8):503-522. PubMed ID: 32218531
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sex-Specific Cardiovascular Risks of Cancer and Its Therapies.
    Wilcox NS; Rotz SJ; Mullen M; Song EJ; Ky Hamilton B; Moslehi J; Armenian SH; Wu JC; Rhee JW; Ky B
    Circ Res; 2022 Feb; 130(4):632-651. PubMed ID: 35175846
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Cardiovascular toxicities associated with immune checkpoint inhibitors].
    Wang WX; Song ZZ; Zhang YP
    Zhonghua Zhong Liu Za Zhi; 2020 Jul; 42(7):609-613. PubMed ID: 32842453
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Use of new and emerging cancer drugs: what the cardiologist needs to know.
    Fabiani I; Chianca M; Aimo A; Emdin M; Dent S; Fedele A; Cipolla CM; Cardinale DM
    Eur Heart J; 2024 Jun; 45(22):1971-1987. PubMed ID: 38591670
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and/or chemotherapy.
    Yu WD; Sun G; Li J; Xu J; Wang X
    Cancer Lett; 2019 Jun; 452():66-70. PubMed ID: 30902563
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cardiotoxicity of Biological Therapies in Cancer Patients: An In-depth Review.
    Madanat L; Gupta R; Weber P; Kumar N; Chandra R; Ahaneku H; Bansal Y; Anderson J; Bilolikar A; Jaiyesimi I
    Curr Cardiol Rev; 2023; 19(3):e310522205428. PubMed ID: 35642110
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pathogenesis of Oral Toxicities Associated with Targeted Therapy and Immunotherapy.
    Villa A; Kuten-Shorrer M
    Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175898
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Heart Failure With Targeted Cancer Therapies: Mechanisms and Cardioprotection.
    Hahn VS; Zhang KW; Sun L; Narayan V; Lenihan DJ; Ky B
    Circ Res; 2021 May; 128(10):1576-1593. PubMed ID: 33983833
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New progress in elucidating the relationship between cancer therapy and cardiovascular toxicity.
    Wu C; Lin D; Ma F; Jiang F; Wang Y
    Biosci Trends; 2021 Sep; 15(4):211-218. PubMed ID: 34305102
    [TBL] [Abstract][Full Text] [Related]  

  • 50. How can we manage the cardiac toxicity of immune checkpoint inhibitors?
    Poto R; Marone G; Pirozzi F; Galdiero MR; Cuomo A; Formisano L; Bianco R; Della Corte CM; Morgillo F; Napolitano S; Troiani T; Tocchetti CG; Mercurio V; Varricchi G
    Expert Opin Drug Saf; 2021 Jun; 20(6):685-694. PubMed ID: 33749484
    [No Abstract]   [Full Text] [Related]  

  • 51. Oncologic therapies associated with cardiac toxicities: how to minimize the risks.
    Cardinale D; Stivala F; Cipolla CM
    Expert Rev Anticancer Ther; 2019 May; 19(5):359-374. PubMed ID: 30916598
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Noninvasive imaging of cardiovascular injury related to the treatment of cancer.
    Kongbundansuk S; Hundley WG
    JACC Cardiovasc Imaging; 2014 Aug; 7(8):824-38. PubMed ID: 25124015
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cardiotoxicity of Contemporary Breast Cancer Treatments.
    Lee Chuy K; Yu AF
    Curr Treat Options Oncol; 2019 May; 20(6):51. PubMed ID: 31073788
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Onco-cardiology: Present and future.
    Sueta D; Hokimoto S
    Int J Cardiol; 2016 Jul; 215():38-40. PubMed ID: 27107544
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio-Oncology Guidelines.
    Alexandre J; Cautela J; Ederhy S; Damaj GL; Salem JE; Barlesi F; Farnault L; Charbonnier A; Mirabel M; Champiat S; Cohen-Solal A; Cohen A; Dolladille C; Thuny F
    J Am Heart Assoc; 2020 Sep; 9(18):e018403. PubMed ID: 32893704
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue.
    Varricchi G; Marone G; Mercurio V; Galdiero MR; Bonaduce D; Tocchetti CG
    Curr Med Chem; 2018; 25(11):1327-1339. PubMed ID: 28403786
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies.
    Baik AH; Oluwole OO; Johnson DB; Shah N; Salem JE; Tsai KK; Moslehi JJ
    Circ Res; 2021 May; 128(11):1780-1801. PubMed ID: 33934609
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Management of Cancer Patients with Cardiovascular Complications - Onco-Cardiology].
    Mukai M
    Gan To Kagaku Ryoho; 2016 Aug; 43(8):940-4. PubMed ID: 27539035
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cardiovascular safety of oncologic agents: A double-edged sword even in the era of targeted therapies - part 1.
    Manolis AA; Manolis TA; Mikhailidis DP; Manolis AS
    Expert Opin Drug Saf; 2018 Sep; 17(9):875-892. PubMed ID: 30126304
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Cardiotoxicity relatively common in cancer treatment].
    Bühlmann Lerjen E; Hübbert L; Papakonstantinou A; Hedayati E; Linde C; Månsson Broberg A
    Lakartidningen; 2016 Jun; 113():. PubMed ID: 27299327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.